Clay Siegall’s contribution to medicine

Clay Siegall is the co-founder and CEO of Seattle Genetics. Prior to founding this organization, he worked with Bristol-Myers Squibb Pharmaceutical Research Institute for six years and worked for the National Cancer Institute for three years. Throughout his career, Mr Siegall has showed interest in developing cancer treatment and therapies.

In co-founding Seattle Genetics, Clay Siegall was able to make his dream come true. Seattle Genetics is a company that focuses on research and development of medical treatments. Under Mr Siegall’s leadership, the organization has been able to come up with a cancer treatment antibody- drug conjugates, ADC, for cancer treatment. Today, there are over 20 ADCs in clinical development that use Seattle Genetics’ technologies in their development. This is only one of their many successful research ventures that have propelled the medical field forward.

Clay Siegall is a PHD holder from George Washington University in Genetics. Since he has a background as a scientist, Mr Siegall has built Seattle Genetics on a foundation of scientific innovation. This is part of the reason why he and the team he works with are open to new ideas. This has enabled them to come up with new ideas that are considered to be problem solving in the field of science.

Every organization needs money to operate. As CEO of Seattle Genetics, Clay Siegall has spear headed many fund raising ventures to support the company. Through his leadership, the organization has managed to raise over 675 us dollars through public and private funding. This money has gone a long way in helping fund research that have contributed significantly to the products they have succeeded to launch in the market. The money raised has also helped ensure that researcher at Seattle Genetics have cutting edge equipment that make their work effective and efficient.

His fulfilment in his work is seeing new medical treatment floated into the market. Finding new ways to help patients get better and eradicate diseases is his joy. Because of this, he strives to lead his team to come up with innovative ways to help propel the medical field foreward.